Enabling a targeted response
Hepatitis C—who’s at risk?
Approximately 130–150 million people have a chronic hepatitis C virus (HCV) infection globally, with 3–4 million new infections occurring each year.1
Certain groups are at increased risk of HCV infection. These include people who inject drugs, children born to mothers with HCV and recipients of infected blood products.
Timely diagnosis is the key to effective treatment
With proper access to diagnostics and treatment, more than 90% of people with hepatitis C can be completely cured within 3–6 months,2 preventing complications such as liver cancer and cirrhosis. However, treatment outcomes are impacted by both the genotype of the virus as well as individual patient characteristics.
Proper diagnosis, along with viral load monitoring, allow healthcare professionals to optimally tailor therapy according to virus genotype, viral load (the amount of virus on the blood), and treatment response rate. By combining pharmaceutical and diagnostic innovations, we can deliver tangible benefits to patients more effectively.
First in innovation
Roche introduced the first-ever test to monitor HCV viral load in 1993 and remains committed to helping eradicate the virus today.
Roche assays support the accurate detection and viral-load quantification of HCV across different genotypes, helping clinicians make decisions that support the best patient care possible.
- World Health Organization (WHO). Fact sheet No. 164: Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed May 13, 2016.
- World Health Organization (WHO). Hepatitis. http://www.who.int/hepatitis/en/. Accessed Nov 3, 2016.